Research location
Bangalore
Karna, India
Advertisement
Research activity in Bangalore
Karna, IndiaCureCurrent currently publishes aggregate city-level research activity for this location: 10 trials and 13 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Bangalore
10 linked trials · page 1 of 1Safety and Efficacy of Cariprazine in SchizophreniaNCT01104779 · 2010-04-27 · 1 site observation
COMPLETED
Multicenter, Open-label, Safety and Tolerability StudyNCT01649557 · 2009-08-01 · 1 site observation
COMPLETED
Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute SchizophreniaNCT00905307 · 2009-07-01 · 1 site observation
COMPLETED
A Study of Cariprazine in Patients With Chronic Stable SchizophreniaNCT00839852 · 2009-05-31 · 2 site observations
COMPLETED
Dose Ranging Study of ART621 in Subjects Diagnosed With Rheumatoid Arthritis Taking MethotrexateNCT00928317 · 2009-04-01 · 2 site observations
TERMINATED
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to LevodopaNCT00627640 · 2009-02-01 · 1 site observation
COMPLETED
Study to Assess the Safety and Tolerability of IV Tonapofylline in Subjects With Acute Decompensated Heart Failure (ADHF) and Renal InsufficiencyNCT00709865 · 2008-07-31 · 1 site observation
COMPLETED
Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of SchizophreniaNCT00694707 · 2008-06-30 · 2 site observations
COMPLETED
Lurasidone HCl A Phase 3 Study of Patients With Acute SchizophreniaNCT00615433 · 2008-01-01 · 1 site observation
COMPLETED
European Study of HF0220 in Mild to Moderate Alzheimer's Disease PatientsNCT00357357 · 2006-07-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.